Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer - Abstract

Purpose: Patients with high-risk prostate cancer (PC) can be treated with high-dose intensity-modulated radiotherapy (IMRT) and long-term androgen deprivation (AD). In this paper we report on (i) late toxicity and (ii) biochemical (bRFS) and clinical relapse-free survival (cRFS) of this combined treatment.

Methods: 126 patients with high-risk PC (T3-4 or PSA >20 ng/mL or Gleason 8-10) and ≥24 months of followup were treated with high-dose IMRT and AD. Late toxicity was recorded. Biochemical relapse was defined as PSA nadir +2 ng/mL. Clinical relapse was defined as local failure or metastases.

Results: The incidence of late grade 3 gastrointestinal and genitourinary toxicity was 2 and 6%, respectively. Five-year bRFS and cRFS were 73% and 86% respectively. AD was a significant predictor of bRFS (P = 0.001) and cRFS (P = 0.01).

Conclusion: High-dose IMRT and AD for high-risk PC offers excellent biochemical and clinical control with low toxicity.

Fonteyne V, Lumen N, Villeirs G, Ost P, De Meerleer G.   Are you the author?
Department of Radiotherapy, Ghent University Hospital, 9000 Ghent, Belgium.

Reference: Adv Urol. 2012;2012:368528.
doi: 10.1155/2012/368528

PubMed Abstract
PMID: 22190918 Prostate Cancer Section